apitope.com
Apitope | Apitope Treatment Approach Published in Nature Communications - Scientists discover how to 'switch off' autoimmune diseases - Apitope
http://apitope.com/apitope-treatment-approach-published-nature-communications-scientists-discover-switch-autoimmune-diseases
Developing new therapies for the treatment of autoimmune and allergic diseases. Leadership & Senior Management Team. Auto-immune Diseases & Allergies. Elimination of Anti-drug Antibodies. Apitope Treatment Approach Published in Nature Communications – Scientists discover how to ‘switch off’ autoimmune diseases. Diepenbeek, Belgium 4th September 2014. Commenting on the research, Dr. Keith Martin, CEO said:. LES USA & Canada 2014 Annual Meeting October 5th 8th San Francisco, USA. One thought on “ Api...
apitope.com
Apitope | Locations - Apitope
http://apitope.com/locations
Developing new therapies for the treatment of autoimmune and allergic diseases. Leadership & Senior Management Team. Auto-immune Diseases & Allergies. Elimination of Anti-drug Antibodies. Apitope’s European Locations. With Locations in both the United Kingdom and Belgium, we make ourselves available to Partner with other pharmaceutical or. Biotechnology companies across the globe. You can find more information about Partnering opportunities with us here. Apitope Technology (Bristol) Ltd.
apitope.com
Apitope | Careers - Apitope
http://apitope.com/careers
Developing new therapies for the treatment of autoimmune and allergic diseases. Leadership & Senior Management Team. Auto-immune Diseases & Allergies. Elimination of Anti-drug Antibodies. We are always interested in hearing from experienced scientists and managers who would like to work with us. Therefore, please feel free to send us your CV using the form below, should you wish to be considered for other vacancies that may arise in the future. Permanent, full time. Quality management and documentation.
apitope.com
Apitope | Discovery Process - Apitope
http://apitope.com/discovery-process
Developing new therapies for the treatment of autoimmune and allergic diseases. Leadership & Senior Management Team. Auto-immune Diseases & Allergies. Elimination of Anti-drug Antibodies. Apitope has established a robust process for identifying tolerogenic peptides. The platform utilizes a number of decision making assay systems that are run internally or with external service providers. Are selected to have the potential to stimulate these cells when presented to them by antigen presenting cells. Has be...
apitope.com
Apitope | News - Apitope
http://apitope.com/news
Developing new therapies for the treatment of autoimmune and allergic diseases. Leadership & Senior Management Team. Auto-immune Diseases & Allergies. Elimination of Anti-drug Antibodies. Apitope to Present at Bio quity Europe in May 2016. Apitope wins prize for presentation at the European Association for Haemophilia and Associated Disorders. Apitope Raises 12 Million in Series B Funding to Progress Treatments for Autoimmune Diseases. Investment led by Wales Life Sciences Fund Cardiff, UK and Hasselt, B...
apitope.com
Apitope | Background to Auto-immunity - Apitope
http://apitope.com/background-auto-immunity
Developing new therapies for the treatment of autoimmune and allergic diseases. Leadership & Senior Management Team. Auto-immune Diseases & Allergies. Elimination of Anti-drug Antibodies. Autoimmune Diseases and Allergies. Treatment and the patient’s quality of life would greatly improve by targeting the fundamental cause of the disease rather than non-specific immune suppression and symptom treatment. The ultimate aim for treatment is to re-instate self-tolerance to an otherwise innocuous self-antig...
apitope.com
Apitope | Pipeline - Apitope
http://apitope.com/pipeline
Developing new therapies for the treatment of autoimmune and allergic diseases. Leadership & Senior Management Team. Auto-immune Diseases & Allergies. Elimination of Anti-drug Antibodies. Product Pipeline – Overview. Apitope has built up an impressive pipeline of potential therapeutic product candidates. Click to view our Pipeline Progress. More about Multiple Sclerosis. More about Factor VIII Intolerance. More about Graves’ Disease. Web design by Nialto Services.
apitope.com
Apitope | Investors - Apitope
http://apitope.com/investors
Developing new therapies for the treatment of autoimmune and allergic diseases. Leadership & Senior Management Team. Auto-immune Diseases & Allergies. Elimination of Anti-drug Antibodies. Apitope was set up with initial funding from the Richard Daniels Family and subsequently support from the Wellcome Trust, Sulis Seedcorn Fund (now Wyvern) and the University of Bristol. As an impact driven Investment Company, LRM is the catalyst for the transition of Limburg’s “production economy” towards an...As an imp...
apitope.com
Apitope | Board of Directors - Apitope
http://apitope.com/board-directors
Developing new therapies for the treatment of autoimmune and allergic diseases. Leadership & Senior Management Team. Auto-immune Diseases & Allergies. Elimination of Anti-drug Antibodies. Stéphane Verdood Non-executive Director; Chairman of the Board. Keith F Martin, PhD, MIoD, MRPharmS Chief Executive Officer. Since April 2006, he has been CEO of Apitope. He led the completion of two successful Phase I clinical trials in multiple sclerosis patients, closed the 10 million Series A (October 2008) and ...
apitope.com
Apitope | Factor VIII Intolerance - Apitope
http://apitope.com/factor-viii-intolerance
Developing new therapies for the treatment of autoimmune and allergic diseases. Leadership & Senior Management Team. Auto-immune Diseases & Allergies. Elimination of Anti-drug Antibodies. Haemophilia A (HA) is a rare chronic bleeding disorder which leads to inadequate clotting of the blood in response to any type of injury or surgery. The most common form of HA is congenital HA, which mostly affects males due to its X-linked recessive inheritance pattern and has an incidence of 1 in 5000.
